|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The STS stroke risk model was surprisingly more discriminating in PCI compared to CABG EXCEL patients.
|
31422924 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients treated with TR approach were more often males, with history of hypertension, and PCI, but less often diabetic, with previous myocardial infarction, coronary artery by-pass graft surgery and cerebrovascular accident.
|
30274753 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
At 36 months MV PCI was associated with similar incidence of the composite endpoint (all-cause death, non-fatal myocardial infarction [MI], ACS-driven, revascularisation, or stroke) in both Cox proportional hazards model (hazard ratio [HR] 1.26; 95% confidence interval [CI] 0.75-2.11; p = 0.39) and propensity matched analysis (HR 1.28; 95% CI 0.75-2.21; p = 0.36).
|
30251246 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Compared to CL-PCI, MV-PCI was associated with a similar risk of bleeding (OR 1.13; 95% CI 0.91-1.40) and stroke (OR 1.28; 95% CI 0.84-1.96), but a higher risk of developing renal failure (OR 1.32; 95% CI 1.05-1.65).
|
30593731 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Four variables (heart failure, left ventricular ejection fraction ≤30%, left main or three vessel CAD, status post (s/p) PCI and s/p stroke) predicted ischemic events, two variables (age>75, haemoglobin <10 g/dL) predicted bleeding.
|
30763340 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial and the Global study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes (GALILEO) trial.
|
29566416 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Activated Protein C- Protein C Inhibitor Complex (APC-PCI) (sensitivity-96%), Glial Fibrillary Acidic Protein (GFAP) (specificity-100%) and a panel of APC-PCI & GFAP (sensitivity- 71%) and Retinol Binding Protein 4 (RBP4) & GFAP (specificity- 100%) were found to have high sensitivity and specificity for differentiating the two stroke types.Our systematic review does not recommend the use of any blood biomarker for clinical purposes yet based on the studies conducted till date.
|
28452132 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall 30-day mortality was similar between concomitant PCI and TAVR versus staged PCI and TAVR [OR: 1.47 (0.47-4.62); P = .51], renal failure was not significantly different between both groups [OR: 3.22 (0.61-17.12); P = .17], periprocedural myocardial infarction was not different between the 2 groups [OR: 1.44 (0.12-16.94); P = .77], life-threatening bleeding did not differ between both groups [OR: 0.45 (0.11-1.87); P = .27], and major stroke also was not significantly different [OR: 3.41 (0.16-74.2); P = .44].
|
29310382 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Percutaneous coronary intervention compared with CABG was associated with a similar long-term composite risk of death, myocardial infarction, or stroke (HR 1.06, 95% CI 0.82-1.37), with fewer events within 30 days after PCI offset by fewer events after 30 days with CABG (P<sub>interaction</sub> < .0001).
|
28760214 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Among patients with significant LMCAD, the long-term risk of the composite outcome of death, myocardial infarction, or stroke was similar between CABG and PCI.
|
29129258 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Likewise, the rates of death [PCI 8% and CABG 7.7%, OR 1(0.77-1.31), P = 0.9], MI [PCI 6.1% vs CABG 5%, OR 1.41(0.85-2.34), P = 0.19, I2 59%], and stroke [PCI 2% vs CABG 2.2%, OR 0.85(0.42-1.81), p = 0.65,] were similar while PCI was associated with a significantly higher rate of TVR [14.5% vs CABG 8.9%, OR 1.73(1.41-2.13), p<0.01].
|
28658308 |
2017 |